{'fraction_non_alphanumeric': 0.023622047244094488, 'fraction_numerical': 0.0, 'mean_word_length': 5.104, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Doxil offers hope to KS sufferers.


 The Food and Drug Administration (FDA) has given market clearance to Doxil, an injectable stealth liposome formulation of doxorubicin, for treatment of Kaposi's sarcoma (KS) in AIDS patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. The drug has a circulating half-life of approximately fifty hours, thus enabling the stealth liposomes to concentrate the encapsulated drug in areas of the body where new blood vessels are being formed and are leaky, such as tumors. To be eligible for the Sequus Pharmaceutical (Doxil) program, patients must meet medical and financial criteria. Interested parties may contact the Doxil Patient Assistance Program.
